Literature DB >> 12065522

In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application.

Anke Lührmann1, Ursula Deiters, Julia Skokowa, Michaela Hanke, Johannes E Gessner, Peter F Mühlradt, Reinhard Pabst, Thomas Tschernig.   

Abstract

Mycoplasmas can cause interstitial pneumonias inducing critical illness in humans and animals. Mycoplasma infections are characterized by an influx of neutrophils, followed by an accumulation of macrophages and lymphocytes. The present study deals with the question of which mycoplasmal components cause this host reaction. The mycoplasma-derived, macrophage-activating lipopeptide 2S-MALP-2 was used to mimic the sequelae of a mycoplasma infection. To this end, 2S-MALP-2 was intratracheally instilled into the lungs of Lewis rats, and the bronchoalveolar lavage cells were examined at different times after different doses of 2S-MALP-2. Application of 2.5 microg induced a pronounced leukocyte accumulation in the bronchoalveolar space. At 24 h after 2S-MALP-2 administration, the majority of leukocytes consisted of neutrophils, followed by macrophages, peaking on days 2 and 3. Lymphocyte numbers, although amounting to only a few percent of the total bronchoalveolar lavage cells, also increased significantly, with maximal lymphocyte accumulation occurring by 72 h after instillation. The leukocyte count of the lung interstitium was increased on day 3 after treatment. After 10 days all investigated cell populations returned to control levels. Transient chemotactic activity for neutrophils was detected in the bronchoalveolar lavage fluid early after 2S-MALP-2 application, followed by monocyte chemoattractant protein-1 activity (MCP-1) in lung homogenates. MCP-1 was produced by bronchoalveolar lavage cells upon stimulation with 2S-MALP-2. Our data indicate that mycoplasmal lipoproteins and lipopeptides are probably the most relevant mycoplasmal components for the early host reaction. The primary target cells are likely to be the alveolar macrophages liberating chemokines, which attract further leukocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065522      PMCID: PMC128036          DOI: 10.1128/IAI.70.7.3785-3792.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

Review 1.  The neutrophil as a cellular source of chemokines.

Authors:  P Scapini; J A Lapinet-Vera; S Gasperini; F Calzetti; F Bazzoni; M A Cassatella
Journal:  Immunol Rev       Date:  2000-10       Impact factor: 12.988

2.  Discrimination of bacterial lipoproteins by Toll-like receptor 6.

Authors:  O Takeuchi; T Kawai; P F Mühlradt; M Morr; J D Radolf; A Zychlinsky; K Takeda; S Akira
Journal:  Int Immunol       Date:  2001-07       Impact factor: 4.823

3.  Eaton agent--science and scientific acceptance: a historical commentary.

Authors:  B P Marmion
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

4.  Mitogenicity and pathogenicity of Mycoplasma pulmonis in rats. I. Atypical interstitial pneumonia induced by mitogenic myeoplasmal membranes.

Authors:  Y Naot; S Davidson; E S Lindenbaum
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

5.  Immune response of pathogen-free mice inoculated intranasally with Mycoplasma pulmonis.

Authors:  G H Cassell; J R Lindsey; H J Baker
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

6.  Production of mastitis in mice with human and bovine ureaplasmas (T-mycoplasmas).

Authors:  C J Howard; J C Anderson; R N Gourlay; D Taylor-Robinson
Journal:  J Med Microbiol       Date:  1975-11       Impact factor: 2.472

7.  Experimental Mycoplasma pulmonis infection in pathogen-free mice. Models for studying mycoplasmosis of the respiratory tract.

Authors:  J R Lindsey; H Cassell
Journal:  Am J Pathol       Date:  1973-07       Impact factor: 4.307

8.  The anti-chlamydial effect of experimental Mycoplasma pulmonis infection in the murine genital tract.

Authors:  M A Tuffrey; P M Furr; P Falder; D Taylor-Robinson
Journal:  J Med Microbiol       Date:  1984-06       Impact factor: 2.472

9.  Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions.

Authors:  M Nishiguchi; M Matsumoto; T Takao; M Hoshino; Y Shimonishi; S Tsuji; N A Begum; O Takeuchi; S Akira; K Toyoshima; T Seya
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

10.  Lymphocyte activation by various Mycoplasma strains and species.

Authors:  Y Naot; J G Tully; H Ginsburg
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

View more
  19 in total

1.  Direct stimulatory effects of the TLR2/6 ligand bacterial lipopeptide MALP-2 on neutrophil granulocytes.

Authors:  Inga Wilde; Sonja Lotz; David Engelmann; Andrea Starke; Ger van Zandbergen; Werner Solbach; Tamás Laskay
Journal:  Med Microbiol Immunol       Date:  2006-09-28       Impact factor: 3.402

2.  Synthetic lipopeptide MALP-2 inhibits intracellular growth of Mycobacterium bovis BCG in alveolar macrophages-preliminary data.

Authors:  Grit Jörgens; Franz-Christoph Bange; Peter F Mühlradt; Reinhard Pabst; Ulrich A Maus; Thomas Tschernig
Journal:  Inflammation       Date:  2009-08       Impact factor: 4.092

3.  Heat shock factor 1 protects against lung mycoplasma pneumoniae infection in mice.

Authors:  Fabienne Gally; Maisha N Minor; Sean K Smith; Stephanie R Case; Hong Wei Chu
Journal:  J Innate Immun       Date:  2011-10-26       Impact factor: 7.349

4.  TLR2/6 stimulation of the rat lung: effects on lymphocyte subsets, natural killer cells and dendritic cells in different parts of the air-conducting compartments and at different ages.

Authors:  Reinhard Pabst; Deniz Durak; Anna Roos; Anke Lührmann; Thomas Tschernig
Journal:  Immunology       Date:  2008-06-19       Impact factor: 7.397

Review 5.  Inhaled therapeutics for prevention and treatment of pneumonia.

Authors:  Amar Safdar; Samuel A Shelburne; Scott E Evans; Burton F Dickey
Journal:  Expert Opin Drug Saf       Date:  2009-07       Impact factor: 4.250

6.  Toll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses.

Authors:  Ursula Deiters; Marina Gumenscheimer; Chris Galanos; Peter F Mühlradt
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

7.  Nickel alterations of TLR2-dependent chemokine profiles in lung fibroblasts are mediated by COX-2.

Authors:  Kelly A Brant; James P Fabisiak
Journal:  Am J Respir Cell Mol Biol       Date:  2007-12-20       Impact factor: 6.914

8.  Beneficial effects of TLR-2/6 ligation in pulmonary bacterial infection and immunization with Pseudomonas aeruginosa.

Authors:  Tanja Kerber-Momot; Damaris Leemhuis; Anke Lührmann; Antje Munder; Burkhard Tümmler; Reinhard Pabst; Thomas Tschernig
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

9.  Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.

Authors:  C Schneider; T Schmidt; C Ziske; K Tiemann; K-M Lee; V Uhlinsky; P Behrens; T Sauerbruch; I G H Schmidt-Wolf; P F Mühlradt; J Schmidt; A Märten
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

10.  Cellular Microbiology of Mycoplasma canis.

Authors:  Dina L Michaels; Jeffrey A Leibowitz; Mohammed T Azaiza; Pollob K Shil; Suzanne M Shama; Gerald F Kutish; Steven L Distelhorst; Mitchell F Balish; Meghan A May; Daniel R Brown
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.